Brentley Q. Smith

Brentley Q. Smith

Auto-generated profile, based on publicly available information

Brentley Q. Smith

Division of Gynecologic Oncology, The Ohio State University The James Comprehensive Cancer Center, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
MGMiranda Gardner
Miranda Gardner
CHColin Lee Hisey
Colin Lee Hisey
RZRoman A. Zingarelli
Roman A. Zingarelli
BSBrentley Q. Smith
Brentley Q. Smith
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
Because of limits on specificity and purity to allow for in-depth protein profiling, a standardized method for exosome isolation has yet to be established. In this study, we describe a novel, in-house microfluidic-based device to isolate exosomes from culture media and patient samples. This technology overcomes contamination issues because sample separation is based on the expression of highly specific surface markers CD63 and EpCAM. Mass spectrometry revealed over 25 exosome proteins that are differentially expressed in high-grade serous ovarian cancer (HGSOC) cell lines compared with normal cells—ovarian surface epithelia cells and fallopian tube secretory epithelial cells (FTSEC). Top exosome proteins were identified on the basis of their fold change and statistical significance between groups. Ingenuity pathway analysis identified STAT3 and HGF as top regulator proteins. We further validated exosome proteins of interest (pSTAT3, HGF, and IL6) in HGSOC samples of origin-based cell lines (OVCAR-8, FTSEC) and in early-stage HGSOC patient serum exosome samples using LC/MS-MS and proximity extension assay. Our microfluidic device will allow us to make new discoveries for exosome-based biomarkers for the early detection of HGSOC and will contribute to the development of new targeted therapies based on signaling pathways that are unique to HGSOC, both of which could improve the outcome for women with HGSOC. Significance: A unique platform utilizing a microfluidic device enables the discovery of new exosome-based biomarkers in ovarian cancer.

1 July 2020 in Journal of Surgical Education
Verified
Journal Article
Closed access
IWIngrid Woelfel
Ingrid Woelfel
DSDavid Strosberg
David Strosberg
BSBrentley Smith
Brentley Smith
AHAlan Harzman
Alan Harzman
RSRitu Salani
Ritu Salani
XCXiaodong Chen
Xiaodong Chen

1 January 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
BSBrentley Q. Smith
Brentley Q. Smith
IWIngrid Woelfel
Ingrid Woelfel
RSRitu Salani
Ritu Salani
AHAlan Harzman
Alan Harzman
XCXiaodong Chen
Xiaodong Chen

31 March 2023
Verified
Other
Open access
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
MGMiranda L. Gardner
Miranda L. Gardner
CHColin Lee Hisey
Colin Lee Hisey
RZRoman A. Zingarelli
Roman A. Zingarelli
BSBrentley Q. Smith
Brentley Q. Smith
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
Supplementary Figures: S1 is a work flow for exosome isolation in cancer cells. S2-S5 is protomic profiling in cancer cells Vs normal cells using different techniques. S6-S8 is The top Canonical pathways identified in the exosome protein

31 March 2023
Verified
Other
Open access
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
MGMiranda L. Gardner
Miranda L. Gardner
CHColin Lee Hisey
Colin Lee Hisey
RZRoman A. Zingarelli
Roman A. Zingarelli
BSBrentley Q. Smith
Brentley Q. Smith
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
Sup. Tables: S1-S3 is Gene Ontology Term analysis by Panther db in cancer cells Vs normal cells. S4-S6 is IPA core analysis showing the top protein molecules identified to be upregulated in cancer cells Vs normal cells. S7 is Proximity Extension Assay for select the Immuno-oncology panel proteins that were significantly higher in HGSOC

31 March 2023
Verified
Other
Open access
KDKalpana Deepa Priya Dorayappan
Kalpana Deepa Priya Dorayappan
MGMiranda L. Gardner
Miranda L. Gardner
CHColin Lee Hisey
Colin Lee Hisey
RZRoman A. Zingarelli
Roman A. Zingarelli
BSBrentley Q. Smith
Brentley Q. Smith
KSKaruppaiyah Selvendiran
Karuppaiyah Selvendiran
Because of limits on specificity and purity to allow for in-depth protein profiling, a standardized method for exosome isolation has yet to be established. In this study, we describe a novel, in-house microfluidic-based device to isolate exosomes from culture media and patient samples. This technology overcomes contamination issues because sample separation is based on the expression of highly specific surface markers CD63 and EpCAM. Mass spectrometry revealed over 25 exosome proteins that are differentially expressed in high-grade serous ovarian cancer (HGSOC) cell lines compared with normal cells—ovarian surface epithelia cells and fallopian tube secretory epithelial cells (FTSEC). Top exosome proteins were identified on the basis of their fold change and statistical significance between groups. Ingenuity pathway analysis identified STAT3 and HGF as top regulator proteins. We further validated exosome proteins of interest (pSTAT3, HGF, and IL6) in HGSOC samples of origin-based cell lines (OVCAR-8, FTSEC) and in early-stage HGSOC patient serum exosome samples using LC/MS-MS and proximity extension assay. Our microfluidic device will allow us to make new discoveries for exosome-based biomarkers for the early detection of HGSOC and will contribute to the development of new targeted therapies based on signaling pathways that are unique to HGSOC, both of which could improve the outcome for women with HGSOC.Significance:A unique platform utilizing a microfluidic device enables the discovery of new exosome-based biomarkers in ovarian cancer.